Lanthanum carbonate is a phosphate-binding medication used to control dangerously high phosphorus levels in people with advanced chronic kidney disease. Approved under the trade name Fosrenol in 2004, it works by grabbing onto dietary phosphate inside the gut before it can be absorbed into the bloodstream, and nearly all of the drug leaves the body in the stool. What makes it distinctive among phosphate binders is what it is not: it contains no calcium and no aluminum, two elements whose long-term accumulation in kidney patients created serious problems that drove the search for alternatives.
Why Phosphate Becomes a Problem in Kidney Disease
Healthy kidneys filter excess phosphorus out of the blood continuously. When kidney function declines past a certain point, phosphorus starts to accumulate. That buildup triggers a cascade of trouble: it pulls calcium out of bones, drives overactivity of the parathyroid glands, and promotes the deposit of calcium-phosphate crystals in blood vessel walls. In dialysis patients especially, uncontrolled high phosphorus has been linked to higher rates of cardiovascular disease and death. Diet restriction alone rarely brings phosphorus down enough, so most people on dialysis end up on one or more phosphate binders taken with every meal.
How Lanthanum Carbonate Binds Phosphate
Lanthanum is a rare-earth metal with a strong chemical attraction to phosphate ions. When you chew or swallow a lanthanum carbonate tablet with food, lanthanum dissociates in the acidic environment of the stomach and then binds tightly to the phosphate released from food as it moves through the digestive tract. The resulting lanthanum-phosphate complex is insoluble, so it passes through and is excreted rather than absorbed.
One practical advantage is that lanthanum’s binding affinity for phosphate holds steady across the full pH range of the gastrointestinal tract, from the acidic stomach to the more neutral small intestine. In laboratory comparisons, lanthanum carbonate showed a higher binding affinity for phosphate than sevelamer hydrochloride at every pH tested, and its binding was less likely to be disrupted by competing substances like bile acids.1PubMed. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride That consistent performance across pH levels is relevant because food and stomach acid don’t always keep the gut at one predictable acidity.
Extremely Low Absorption
A recurring concern with any metal-based phosphate binder is whether the metal accumulates in the body over time. For lanthanum carbonate, the reassuring finding is that almost none of it gets absorbed. In a study measuring the absolute bioavailability in healthy volunteers, the fraction of lanthanum that actually reached the bloodstream was roughly 0.001%, with individual values ranging from about 0.0002% to 0.002%.2PubMed. Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate To put that in perspective, if you took a full therapeutic dose, the amount entering your circulation would be vanishingly small.
The tiny fraction that does get absorbed is cleared almost entirely through bile, not through the kidneys. Renal clearance after oral dosing was negligible, around 1.4 mL per minute, which is reassuring for people whose kidneys are already compromised.3PubMed. Clinical pharmacokinetics of the phosphate binder lanthanum carbonate Research in intestinal fluid showed that over 99.9% of lanthanum carbonate precipitated out of solution, meaning essentially all of the drug stays in the gut lumen and never crosses the intestinal wall in any meaningful quantity.4Metallomics. Lanthanum carbonate, a potent and selective phosphate binder, is transported and absorbed mainly via M cells in gastrointestinal tract
How Well It Controls Phosphorus
Clinical trials have consistently shown that lanthanum carbonate brings serum phosphorus down to a degree comparable to other standard phosphate binders. A systematic review found that lanthanum carbonate, calcium carbonate, and sevelamer hydrochloride were broadly similar in controlling serum phosphorus, the calcium-phosphorus product, and parathyroid hormone levels.5PubMed Central. Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review A guideline review from the National Kidney Foundation echoed that assessment, noting that efficacy for lanthanum carbonate appears similar to other binders.6American Journal of Kidney Diseases. State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective
One claim that has appeared in older literature is that lanthanum carbonate’s phosphate-lowering effect is roughly twice that of calcium carbonate.7PubMed Central. The management of hyperphosphatemia by lanthanum carbonate in chronic kidney disease patients Whether that translates to a clinical advantage in head-to-head trials is less clear, since most randomized comparisons titrate each drug to a target phosphorus level rather than comparing fixed doses. The more consistent finding is that lanthanum carbonate gets phosphorus to goal as reliably as the alternatives, and its advantages show up in other areas like calcium load and vascular calcification.
An important caveat surfaced in the COMBINE trial, which tested lanthanum carbonate at 1 g three times daily for 12 months in patients with earlier-stage kidney disease who were not yet on dialysis. In that study, lanthanum did not significantly lower serum phosphate, though it did modestly reduce urinary phosphate and FGF23, a hormone tied to phosphate metabolism.8American Journal of Kidney Diseases. State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective The implication is that in people whose phosphorus isn’t dramatically elevated yet, the drug may not produce the dramatic serum drop seen in dialysis patients.
The Vascular Calcification Advantage
Where lanthanum carbonate starts to look more interesting than “just another binder” is in its effects on blood vessel calcification. Calcium-based phosphate binders, by definition, deliver a calcium load with every dose. In patients already prone to calcium deposits in their arteries, this extra calcium can accelerate the hardening of blood vessels. Lanthanum carbonate avoids this entirely because it contains no calcium.
In a pilot study comparing lanthanum carbonate with calcium carbonate in hemodialysis patients, coronary artery calcification scores actually decreased slightly in the lanthanum group over 12 months while increasing by about 41% in the calcium group.9PubMed. Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: a pilot study A separate randomized trial looking at aortic calcification found significantly less progression over 18 months in the lanthanum group.10PubMed. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial A systematic review and meta-analysis concluded that lanthanum carbonate was associated with less vascular calcification progression and better bone outcomes compared with calcium-based binders, without the aluminum-like toxicity that plagued older phosphate binders.11PubMed. Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis
Separate research has also explored why lanthanum compounds might directly interfere with the calcification process itself. In vascular smooth muscle cells, lanthanum chloride appeared to inhibit calcium deposition and osteogenic differentiation, and to alter the crystal structure of hydroxyapatite deposits.12PubMed Central. Lanthanum Chloride in Vascular Calcification: Effects on Nano-Hydroxyapatite and PPARγ/Wnt/β-Catenin This is still early-stage mechanistic work, but it suggests that lanthanum may have anti-calcification properties beyond simply avoiding a calcium load.
When compared with sevelamer hydrochloride, the other major non-calcium binder, lanthanum carbonate performed similarly for phosphorus lowering but led to less intestinal calcium absorption after a meal.13PubMed Central. Different Effect of Lanthanum Carbonate and Sevelamer Hydrochloride on Calcium Balance in Patients with Moderate to Advanced Chronic Kidney Disease Whether that difference meaningfully changes long-term cardiovascular outcomes is still an open question.
Survival Data
The hardest endpoint to demonstrate for any phosphate binder is whether it actually helps people live longer. One observational study in hemodialysis patients found a survival benefit associated with lanthanum carbonate, but only in patients whose phosphorus was poorly controlled (above 6.0 mg/dL). In that subgroup, lanthanum use was associated with roughly half the risk of death compared with other binders. In patients whose phosphorus was already at or below 6.0, there was no survival difference.14Nephrology Dialysis Transplantation. Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia This makes intuitive sense: a more potent binder matters most when phosphorus is hardest to control.
Side Effects and Tolerability
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and abdominal discomfort. These tend to be mild to moderate and are similar to the side-effect profile of other phosphate binders.15PubMed. Lanthanum carbonate The practical difference is what lanthanum carbonate doesn’t cause. Episodes of high blood calcium occurred significantly less often with lanthanum carbonate than with calcium carbonate over six months, which matters because high calcium carries its own cardiovascular risks in kidney patients.16PubMed. Lanthanum carbonate
Long-term safety data have been generally reassuring. The NKF-KDOQI review noted that long-term outcome data support safety, without the nervous system or bone side effects that made aluminum-based binders infamous.17American Journal of Kidney Diseases. State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective In animal models, high doses of lanthanum carbonate in the setting of kidney failure did cause changes in bone formation rate, but these appeared to result from phosphate depletion rather than any direct toxic effect of lanthanum on bone cells.18PubMed. Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?
Tissue Deposition Concerns
Despite the extremely low absorption rate, lanthanum does accumulate at low levels in certain tissues over time, including bone, liver, mesenteric lymph nodes, and plasma.19PubMed Central. Lanthanum deposition from oral lanthanum carbonate in the upper gastrointestinal tract Animal studies have confirmed that the liver is the primary site of accumulation, with smaller amounts found in bone, kidney, and brain tissue.20PubMed Central. Lanthanum carbonate possibly responsible for acute liver failure in a patient with Child–Pugh stage A liver cirrhosis A case report documented acute liver failure in a patient with pre-existing cirrhosis who was taking lanthanum carbonate, raising the possibility that people with compromised liver function might be more vulnerable.21PubMed Central. Lanthanum carbonate possibly responsible for acute liver failure in a patient with Child–Pugh stage A liver cirrhosis
Whether these low-level tissue deposits cause harm over years or decades of use is one of the genuine unknowns. The concentrations are small, and large clinical studies haven’t flagged organ toxicity as a significant problem. But kidney patients often take phosphate binders for the rest of their lives, and the long-term data, while reassuring so far, can never be long enough to put the question entirely to rest.
The Radiopaque Imaging Problem
One quirk of lanthanum carbonate that catches clinicians off guard is that lanthanum is a dense metal. It shows up bright white on X-rays and CT scans, and when it accumulates in the lining of the gastrointestinal tract or simply remains as undissolved residue, it can mimic the appearance of something alarming. A systematic review of case reports found that lanthanum-related opacities were identified on X-ray in about 73% of published cases and on CT in roughly 49%.22PubMed Central. Lanthanum Carbonate Opacities—A Systematic Review
In at least one documented case, lanthanum deposits were mistaken for swallowed foreign bodies, triggering extensive workups including serial imaging, surgical consultations, and unnecessary alarm.23PubMed Central. Lanthanum-Induced Radiopaque Intestinal Precipitates: A Potential Cause of Intestinal Foreign Bodies For anyone taking lanthanum carbonate, it’s worth mentioning the medication to radiologists and emergency physicians before imaging, since the white spots on a scan have a benign explanation that can save everyone a lot of trouble.
Drug Interactions
Because lanthanum carbonate binds substances in the gut, it can interfere with the absorption of other medications taken at the same time. The best-documented interaction is with levothyroxine, the thyroid hormone replacement taken by millions of people. Research has confirmed that lanthanum carbonate reduces levothyroxine absorption.24PubMed Central. Colesevelam hydrochloride and lanthanum carbonate interfere with the absorption of levothyroxine The general advice is to separate the two medications by at least two hours. The same caution applies to other drugs that are sensitive to binding interactions in the gut, including certain antibiotics and some anticonvulsants, though data on specific combinations beyond levothyroxine are less extensive.
Tablet Burden and Oral Powder
Phosphate binders are notorious for being among the highest pill-burden medications that dialysis patients take. Lanthanum carbonate was originally available only as a large chewable tablet, and some patients found the tablets difficult to chew or unpleasant in taste. An oral powder formulation was later developed. In a study of hemodialysis patients switched from chewable tablets to the powder, serum phosphorus levels actually improved modestly, dropping from an average of 5.3 to 4.9 mg/dL after one month.25PubMed. Efficacy of oral powder compared with chewable tablets for lanthanum carbonate administration in hemodialysis patients The likely explanation is better adherence: if the medication is easier to take, people actually take it.
Adherence studies paint a mixed picture. In a survey of French and Spanish patients with end-stage kidney disease, roughly 52% to 66% were considered adherent to the powder formulation, but that rate was statistically no different from their adherence to whatever phosphate binder they had been using before.26PubMed Central. Lanthanum carbonate oral powder: satisfaction, preference and adherence in French and Spanish patients with end-stage renal disease Phosphate binder adherence is a persistent problem across the board, not specific to lanthanum carbonate. Patients take these medications with every meal, every day, and that kind of regimen wears people down regardless of the formulation.
Use in Children and Adolescents
High phosphorus is also a concern in children with advanced kidney disease, but most phosphate binders were developed and tested in adults. A phase 2 trial assessed lanthanum carbonate in children and adolescents on dialysis. After eight weeks of treatment, 50% of patients achieved phosphorus control. Among patients who had first received calcium carbonate and then switched to lanthanum carbonate, over 70% reached the target. Both drugs were generally well tolerated in the pediatric group.27PubMed Central. An open-label phase 2 trial to assess the efficacy, safety and pharmacokinetics of lanthanum carbonate in hyperphosphatemic children and adolescents with chronic kidney disease undergoing dialysis Pediatric data remain thin compared with adult evidence, but this trial at least established that lanthanum carbonate can work and appears safe in younger patients.
Cost-Effectiveness
The economics of phosphate binders are surprisingly contentious. Lanthanum carbonate and sevelamer are both more expensive per tablet than calcium-based binders, so the question is whether their advantages in avoiding calcium loading and vascular calcification justify the higher price.
The answer seems to depend heavily on the health-care system and patient population. A systematic review of economic evaluations found that lanthanum carbonate was more cost-effective than calcium-based binders in high-income countries, with a meaningful net benefit when used in pre-dialysis patients or as a second-line option.28PubMed Central. Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations A Spanish cost-effectiveness analysis found that lanthanum carbonate actually dominated calcium-based binders outright, meaning it cost less and produced slightly more quality-adjusted life years over the simulation period.29PubMed Central. Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis
The comparison with sevelamer is more nuanced. One U.S. analysis found that switching from sevelamer to lanthanum carbonate saved an average of about $11 per day in drug costs while maintaining the same phosphorus levels, with the savings greatest for patients who had been on high doses of sevelamer.30PubMed. Cost-minimization analysis of lanthanum carbonate versus sevelamer hydrochloride in US patients with end-stage renal disease However, a different cost-effectiveness model found that lanthanum was “dominated” when compared against other options, meaning it delivered less value per dollar in that particular analytic framework.31PubMed. Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease The discrepancy likely comes down to differences in modeling assumptions, time horizons, and which downstream costs are included. For individual patients, the practical calculus often involves how many tablets per day each option requires and whether insurance or national formulary covers one binder preferentially over another.
Lanthanum Carbonate Beyond Medicine
Lanthanum’s affinity for phosphate has attracted interest well outside nephrology. Excess phosphorus in lakes, rivers, and wastewater triggers algal blooms that can be toxic to aquatic life and make water undrinkable. Researchers have been developing engineered lanthanum carbonate adsorbents to remove phosphate from water sources at very low concentrations. One approach uses a high-gravity-assisted method to synthesize lanthanum carbonate particles with different shapes and structures optimized for phosphate capture.32Separation and Purification Technology. High-gravity-assisted controlled synthesis of lanthanum carbonate for highly-efficient adsorption of phosphate Another strategy modifies lanthanum carbonate with iron to boost its performance at ultra-low phosphate concentrations, the range where conventional water treatment struggles most.33Chemical Engineering Journal. Insight into heterovalent metal modification for lanthanum carbonate to enhance phosphate removal at trace levels The same chemistry that makes lanthanum carbonate effective in the gut turns out to be useful for cleaning up waterways, which is a satisfying bit of overlap between pharmacology and environmental engineering.